CRISPR upstart Casebia picks Sanofi vet Burns as new CEO; On the heels of a trial debacle, Opexa sheds staffers
Jim Burns, who had headed Sanofi’s R&D ops in Boston, is jumping ship to take the helm of Casebia Therapeutics, the $335 million gene …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
